Akero Therapeutics AKRO 深 沪
交易中 08-12 10:15:29 美东时间
47.74
-0.540
-1.12%
华盛通- 最 高48.6972
- 今 开48.42
- 成交量 4.71万股
- 最 低 47.62
- 昨 收 48.28
- 总市值 38.06亿
- 52周最高 58.40
- 市盈率 静 --
- 换手率 0.06%
- 52周最低 21.34
- 委 比 -88.47%
- 总股本 7971.76万
- 历史最高 58.40
- 量 比 0.40
- 振 幅 2.23%
- 历史最低 7.52
- 每 手 1
- 风险率 10.53%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Akero Therapeutics Q2 EPS $(0.86) Beats $(0.93) Estimate
Akero Therapeutics (NASDAQ:AKRO) reported quarterly losses of $(0.86) per share which beat the analyst consensus estimate of $(0.93) by 7.53 percent. This is a 6.17 percent decrease over losses of $(0.81) per share from
08-08 19:18
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Akero Therapeutics reported second quarter 2025 financial results, with $1.086 billion in cash and marketable securities, and highlighted key advancements for EFX, its lead candidate for MASH. Phase 2b SYMMETRY study data, published in the New England Journal of Medicine, demonstrated statistically significant reversal of compensated cirrhosis (F4) in patients with MASH. Additional findings at EASL 2025 showed EFX's potential to benefit high-risk...
08-08 11:15
TD Cowen Initiates Coverage On Akero Therapeutics with Buy Rating, Announces Price Target of $76
TD Cowen analyst Ritu Baral initiates coverage on Akero Therapeutics (NASDAQ:AKRO) with a Buy rating and announces Price Target of $76.
08-04 19:38
恒申安科罗年产10万吨改性塑料项目动工
近日，恒申安科罗年产10万吨改性工程材料项目正式动工建设，一期产能为5万吨。据悉，该项目总投资10亿元，占地面积110亩，总建筑面积约15万平方米。企业规划建设...
07-22 18:12
Akero Therapeutics’ Efruxifermin Study: A Potential Game-Changer for NASH/MASH Treatment
Akero Therapeutics (($AKRO)) announced an update on their ongoing clinical stud...
06-27 00:23
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
Akero Therapeutics announced that its management will present at the Jefferies Global Healthcare Conference on June 4, 2025. The presentation will be webcast live and archived on the company's website. Akero develops treatments for serious metabolic diseases like metabolic dysfunction-associated steatohepatitis (MASH). Its lead candidate, efruxifermin (EFX), is in Phase 3 trials. The company is based in South San Francisco.
05-28 11:00
美股大行评级 | 潜在涨幅1562.13%！Cingulate获Ascendiant Capital升目标价至61美元，维持"买入"评级
潜在涨幅1562.13%！Cingulate获Ascendiant Capital升目标价至61美元，维持"买入"评级
05-28 09:04
B of A Securities Maintains Buy on Akero Therapeutics, Raises Price Target to $64
B of A Securities analyst Alexandria Hammond maintains Akero Therapeutics (NASDAQ:AKRO) with a Buy and raises the price target from $63 to $64.
05-27 23:20
美股牛股 | 月内累涨超640%！脑再生科技再涨27%；量子计算股QBTS升超25%
月内累涨超640%！脑再生科技再涨27%；QBTS发布新一代量子计算系统，股价飙升超25%>>
05-21 18:45
